Research graph
References from Mismatch Repair–Proficient Colorectal Cancer Can Evade Immune Surveillance through an Intrinsic Suppressive Program. Local targets link to admitted publications; unresolved targets remain external evidence.
Comprehensive molecular characterization of human colon and rectal cancer
10.1038/nature11252 · 2012 · External reference
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
10.1038/sj.bjc.6604867 · 2009 · External reference
Immunotherapy in colorectal cancer: rational, challenges and potential
10.1038/s41575-019-0126-x · 2019 · External reference
Enhancing anti-tumor efficacy with immunotherapy combinations
10.1016/s0140-6736(20)32598-8 · 2021 · External reference
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
10.1126/science.aan6733 · 2017 · External reference
Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup
10.1016/j.annonc.2022.10.003 · 2023 · External reference
Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond
10.1007/s11523-019-00690-0 · 2020 · External reference
FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors
10.1158/1078-0432.ccr-21-0327 · 2021 · External reference
Association of tumor mutational burden with outcomes in patients with advanced solid tumors treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
10.1016/s1470-2045(20)30445-9 · 2020 · External reference
Pembrolizumab in microsatellite-instability-high advanced colorectal cancer
10.1056/nejmoa2017699 · 2020 · External reference
Neoadjuvant Immunotherapy leads to pathological responses in MMR proficient and MMR deficient early-stage colon cancers
10.1038/s41591-020-0805-8 · 2020 · External reference
PD-1 Blockade in mismatch repair-deficient, locally advanced rectal cancer
10.1056/nejmoa2201445 · 2022 · External reference
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
10.1200/jco.2017.76.9901 · 2018 · External reference
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate142
10.1016/j.annonc.2022.06.008 · 2022 · External reference
First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
10.1200/jco.21.01015 · 2022 · External reference
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients
10.1158/2159-8290.cd-21-1434 · 2022 · External reference
Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial
10.1200/jco.21.02583 · 2022 · External reference
Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer
10.1016/j.ccell.2025.05.010 · 2025 · External reference
Immune activation in mismatch repair-deficient carcinogenesis: more than just mutational rate
10.1158/1078-0432.ccr-18-0856 · 2020 · External reference
Primary, adaptive and aquired resistance to cancer immunotherapy
10.1016/j.cell.2017.01.017 · 2017 · External reference
Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
10.1038/s41587-022-01547-0 · 2023 · External reference
Tumor organoid-T-cell coculture system
10.1038/s41596-019-0232-9 · 2020 · External reference
Generation of tumor-reactive T cells by coculture of peripheral blood lymphocytes and tumor organoids
10.1016/j.cell.2018.07.009 · 2018 · External reference
Integrated peripheral blood multi-omics profiling identifies immune signatures predictive of neoadjuvant PD-1 blockade efficacy in head and neck squamous cell carcinoma
10.1186/s12967-025-06770-2 · 2025 · External reference
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia
10.1016/j.ccell.2022.04.001 · 2022 · External reference
Glycosylation in cancer: mechanisms and clinical implications
10.1038/nrc3982 · 2015 · External reference
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy
10.1136/jitc-2025-012391 · 2025 · External reference
Decoding the glycoproteome: a new frontier for biomarker discovery in cancer
10.1186/s13045-024-01532-x · 2024 · External reference
Siglecs and their roles in the immune system
10.1038/nri2056 · 2007 · External reference
Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies
10.1126/scitranslmed.abg3072 · 2022 · External reference
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
10.1038/ncomms12632 · 2016 · External reference
Inactivation of DNA repair triggers neoantigen generation and impair tumour growth
10.1038/nature24673 · 2017 · External reference
Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response
10.1126/science.aau0447 · 2019 · External reference
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models
10.1016/j.ccell.2025.05.014 · 2025 · External reference
Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy
10.1016/j.ccell.2019.06.008 · 2019 · External reference
Targeting glycosylation: a new road for cancer drug discovery
10.1016/j.trecan.2020.04.002 · 2020 · External reference
The PRIDE database at 20 years: 2025 update
10.1093/nar/gkae1011 · 2025 · External reference
